Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
- Conditions
- ADHD
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00141050
- Locations
- 🇺🇸
Bayou City Research, Houston, Texas, United States
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
- Conditions
- ADHD
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00141063
- Locations
- 🇺🇸
Center for Psychiatry & Behavioral Medicine, Las Vegas, Nevada, United States
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
- Conditions
- HypertensionLeft Ventricular Hypertrophy
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 125
- Registration Number
- NCT00139555
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation
- Conditions
- Constipation
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 600
- Registration Number
- NCT00139568
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- Novartis
- Registration Number
- NCT00139581
- Locations
- 🇨🇭
This study is not being conducted in the United States, Novartis Pharma AG, Basel, Switzerland
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 181
- Registration Number
- NCT00139594
- Locations
- 🇺🇸
Investigational site, La Palma, California, United States
🇻🇪Novartis Investigational Site, Caracas, Venezuela
🇺🇸Novartis Investigational site, West Allis, Wisconsin, United States
Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 180
- Registration Number
- NCT00138593
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 179
- Registration Number
- NCT00138606
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇩🇪Novartis Investigative Site, Investigative Centers, Germany
Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome
- Conditions
- Metabolic Syndrome
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 55
- Registration Number
- NCT00138528
- Locations
- 🇩🇪
Novartis, Nürnberg, Germany
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 345
- Registration Number
- NCT00138580
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States